Pinch the skin gently if instructed by your healthcare provider

Product Attributes CAS # : 121062-08-6 Molecular Formula : C50H69N15O9 Sequence (AA) : Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 Molecular Weight : 1024.18 g/mol PubChem CID : 92432 Half-Life : ~30 60 min Synonyms : MT-2, Melanotan-II, Melanocortin Analog, NDP -MSH Type : Synthetic cyclic peptide analog of -MSH Research Focus : Beauty & Skin, Libido & Reproduction Scientific References Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study Human RCT Melanotan II user experience: a qualitative study of online discussion Observational Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Observational Melanotan II: a possible cause of renal infarction: review of the literature and case report Observational Evidence that melanocortin receptor agonist melanotan-II synergistically augments the ability of naltrexone to blunt binge-like ethanol intake in male C57BL/6J mice Animal Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internet In vitro Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide In vitro Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers Human RCT Melanotan II an overview Animal A glimpse into the underground market of melanotan Observational Case report melanotan tanning injection: a rare cause of priapism Observational Melanotan | Actas dermo-sifiliogrficas In vitro Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator

People do lose weight using EllieMD products
Not all do, so ask upfront
butyricum GKB7 supplementation on (A) hepatic glycogen content and (B) skeletal muscle glycogen content
Implications for innovation In a difficult period for new product launches, many brands have looked to the growing number of GLP-1 users as a target for innovation